Results 171 to 180 of about 16,411 (192)
Some of the next articles are maybe not open access.

Edoxaban

Reactions Weekly, 2019
  +6 more sources

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

New England Journal of Medicine, 2021
Martin Unverdorben   +2 more
exaly  

Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial

Circulation, 2023
Yugo Yamashita   +2 more
exaly  

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

Lancet, The, 2019
Pascal Vranckx   +2 more
exaly  

Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation

New England Journal of Medicine, 2020
Ken Okumura   +2 more
exaly  

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

Lancet, The, 2015
Eugene Braunwald   +2 more
exaly  

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Lancet, The, 2016
Andreas Goette   +2 more
exaly  

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

New England Journal of Medicine, 2013
Eugene Braunwald   +2 more
exaly  

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

New England Journal of Medicine, 2013
Harry R Büller   +2 more
exaly  

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial

Lancet, The, 2015
Elliott M Antman   +2 more
exaly  
atrial fibrillation
stroke
venous thromboembolism
medicine
factor xa inhibitors
anticoagulants
therapeutics
pharmacology
anticoagulant
previous   16  17  18  19  20  

Home - About - Disclaimer - Privacy